Lung Cancer Highlights: ASCO 2022

CME

Key Studies in Lung Cancer: Independent Conference Coverage of ASCO 2022

Physicians: Maximum of 1.25 AMA PRA Category 1 Credits

Released: September 01, 2022

Expiration: August 31, 2023

Stephen V. Liu
Stephen V. Liu, MD
Zofia Piotrowska
Zofia Piotrowska, MD

Activity

Progress
1
Course Completed

In this module, Stephen V. Liu, MD, and Zofia Piotrowska, MD, MHS, discuss key findings in the management of lung cancer presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, including updates in advanced and early-stage non-small-cell lung cancer (NSCLC) and relapsed small-cell lung cancer (SCLC).

Please note that the key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slidesets, which can be found here or downloaded by clicking any of the slide thumbnails in the module alongside the expert commentary.

Clinical Care Options plans to measure the educational impact of this activity. A few questions will be asked twice: once at the beginning of the activity and then again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

If you are a practicing healthcare professional, how many patients with lung cancer do you provide care for in a typical month?

In your current practice, which of the following approaches would you recommend to optimize outcomes for a patient with newly diagnosed resectable stage IIIA NSCLC (single station, non-bulky N2) that pathology reported as PD-L1 <1% and EGFR/ALK wild type on testing of the fine-needle aspirate specimen?

A patient with previously treated, advanced NSCLC and which of the following genetic alterations may benefit from participation in a clinical trial of the investigational agent CLN-081?

All of the following findings were reported from the phase II OPAL trial of osimertinib plus 4 cycles of platinum/pemetrexed doublet therapy followed by maintenance therapy with osimertinib and pemetrexed in previously untreated patients with advanced EGFR mutation–positive nonsquamous NSCLC EXCEPT which one?